Introduction
============

Metformin-induced hemolytic anemia has been reported in three patients, all of whom recovered when metformin was discontinued \[[@B1]-[@B3]\]. We report the case of a patient with fulminant and fatal hemolysis that occurred shortly after metformin was started for the treatment of type 2 diabetes mellitus.

Case presentation
=================

A 56-year-old Caucasian man with type 2 diabetes mellitus, hypothyroidism, idiopathic thrombocytopenic purpura status post splenectomy in 1979, and remote testicular cancer status post orchiectomy and radiation therapy in the 1970s was admitted with 2 days of progressive fatigue, exertional dyspnea, low back pain and cranberry-colored urine. He had been started on metformin 500 mg twice a day 4 days previously for type 2 diabetes but called in to his physician the following day with complaints of \"palpitation, heavy breathing, and tossing and turning last night\" after taking the metformin, which he declined to continue. Two days before admission he was seen at an outside emergency room with hematuria and anemia; he was diagnosed with a urinary tract infection and started on oral ciprofloxacin. His other medications were pantoprazole, levothyroxine and glyburide. On the day of admission, vital signs were temperature 37.1°C, pulse rate of 133 per minute, respiration rate of 32 breaths per minute, blood pressure of 155/84 and pulse oxygen 94% on 6 liters O~2~. Physical examination was significant for respiratory distress, scleral icterus and generalized jaundice. There was no jugular venous distention and no enlarged thyroid gland or lymphadenopathy. His lungs were clear, heart sounds were distant, his abdomen was soft without masses or enlargement of organs, he had no rashes and no peripheral edema. Mild lumbar and thoracic spinous tenderness was noted; neurological examination revealed mild lethargy but otherwise normal mental status, with no focal findings. Laboratory studies (Table [1](#T1){ref-type="table"}) were significant for hemoglobin of 6.6 g/dl, which had dropped from 14.7 g/dl 4 days before, total bilirubin 6.6 mg/dl (direct 2.7 mg/dl), reticulocyte count 3.51%, lactate dehydrogenase 4829 U/l, and haptoglobin less than 6 mg/dl, all consistent with severe hemolysis. The direct antiglobulin (Coombs) test (DAT) was positive for anti-IgG and negative for anti-C3. The peripheral blood smear on admission significantly showed no schistocytes; 4% immature granulocytes and 4% nucleated red blood cells (RBCs) were noted. Other significant findings included marked leukocytosis to 46.1 K/cmm, acute renal failure, elevation of troponin-I and marked transaminase elevations (aspartate aminotransferase (AST) 1711, alanine aminotransferase (ALT) 806) with normal international normalized ratio and alkaline phosphatase. Blood and urine cultures showed no growth. Despite treatment with corticosteroids and transfusion of packed RBCs, the patient became increasingly dyspneic and agitated, complained of abdominal pain and developed hypotension followed by cardiorespiratory arrest approximately 8 hours after admission. Over the next 4 hours he was treated following the advanced cardiac life support protocol for recurrent bouts of pulseless electrical activity and asystole, with worsening hyperkalemia and metabolic acidosis. Despite transfusion, hemoglobin was noted to have declined to 3.3 g/dl. The patient died approximately 12 hours after admission.

###### 

Laboratory test results

  Variable                         11/21/2006   11/20/2006   11/16/2006   9/21/2006   Units
  -------------------------------- ------------ ------------ ------------ ----------- ---------
  Hemoglobin                       3.3          6.6          14.7         \-          g/dl
  Hematocrit                       10.2         19.5         43.3         \-          \%
  Platelet                         97           166          322          \-          K/cmm
  White blood cell                 44.0         46.1         11.5         \-          K/cmm
  Glucose                          \-           277          \-           220         mg/dl
  Blood urea nitrogen              \-           38           \-           22          mg/dl
  Creatinine                       \-           2.4          \-           1.1         mg/dl
  Sodium                           \-           129          \-           140         meq/l
  Potassium                        \-           5.5          \-           4.5         meq/l
  Chloride                         \-           94           \-           104         meq/l
  CO~2~                            \-           15           \-           27          mmol/l
  Calcium                          \-           8.7          \-           9.2         mg/dl
  Lactate dehydrogenase            \-           4829         \-           \-          U/l
  Haptoglobin                      \-           \<6          \-           \-          mg/dl
  Fibrinogen                       \-           253          \-           \-          mg/dl
  Total bilirubin                  \-           6.9          \-           0.8         mg/dl
  Direct bilirubin                 \-           \-           \-           0.1         mg/dl
  Alkaline phosphatase             \-           103          \-           83          U/l
  Alanine aminotransferase         \-           806          \-           38          U/l
  Aspartate aminotransferase       \-           1711         \-           31          U/l
  Creatine phosphokinase           \-           597          \-           \-          U/l
  Partial thromboplastin time      \-           26.7         \-           \-          seconds
  International normalized ratio   \-           1.22         \-           \-          \-

Discussion
==========

The temporal relationship with metformin ingestion is strong in this case, with the patient noting symptoms within hours of the initiation of metformin. The 4-day course was rapid and fatal, characterized by massive hemolysis and shock. In the three previously reported cases of metformin-induced hemolytic anemia (Table [2](#T2){ref-type="table"}), the time to onset of symptoms ranged from 9 to 14 days after starting metformin, and none resulted in massive hemolysis or death. Glucose-6-phosphate dehydrogenase (G6PD) levels and the results of the DAT were variable. In two of the three cases the hemolysis recurred with metformin rechallenge, which increases the likelihood of a causal relationship according to the Naranjo adverse drug reaction probability scale \[[@B4]\].

###### 

Reported cases of metformin-induced hemolytic anemia

  Case report                     Patient\'s age (years)   Gender   Time from starting metformin to onset of symptoms   Direct Coombs          G6PD level   Recurrence of hemolysis with metformin rechallenge   Outcome
  ------------------------------- ------------------------ -------- --------------------------------------------------- ---------------------- ------------ ---------------------------------------------------- ----------
  Lin et al. \[[@B1]\]            46                       Male     10 days                                             \'Equivocal\'          Normal       Yes                                                  Recovery
  Kashyap and Kashyap \[[@B2]\]   51                       Female   9 days                                              Positive (-IgG, +C3)   Normal       Yes                                                  Recovery
  Meir et al. \[[@B3]\]           68                       Female   14 days                                             Negative               Decreased    N/A                                                  Recovery
  Packer et al. (this study)      56                       Male     1 to 2 days                                         Positive (+IgG, -C3)   N/A          N/A                                                  Death

Other possible causes of fulminant hemolysis must be considered in this patient. The lack of schistocytes makes micro-angiopathic processes such as thrombotic thrombocytopenic purpura (TTP) or disseminated intravascular coagulation less likely. In addition, the absence of fever and the patient\'s normal platelet count reduce the likelihood of TTP. There are several case reports of ciprofloxacin-induced hemolysis \[[@B5]\], but our patient had already developed anemia and hemoglobinuria suggestive of ongoing hemolysis before being started on ciprofloxacin in the emergency room. Another possibility is Evans syndrome, which is a DAT-positive hemolytic anemia and immune thrombocytopenia with no known underlying etiology. Evans syndrome causes chronic hemolytic anemia, which our patient did not have, and it is rarely fulminant. A third possibility is hemolytic anemia associated with acute hepatitis, most commonly hepatitis A, which has been described as a cause of fulminant and sometimes fatal hemolysis in patients with G6PD deficiency \[[@B6],[@B7]\]. As hepatitis serologies and G6PD levels are not available for this patient, it is impossible to rule out acute hepatitis as the underlying cause of the hemolysis. However, at an office visit 4 days prior to admission, this patient had no prodromal signs or symptoms of hepatitis, and nothing in his travel or dietary history was suggestive of a risk for hepatitis A. In addition, hemolysis can cause a significant increase in AST and a more moderate increase in ALT owing to the release of these transaminases from the lysed RBCs \[[@B8]\]. As there is more AST than ALT in RBCs, a high AST-to-ALT ratio would be expected in a case of hemolysis-induced transaminitis. The presence a high AST-to-ALT ratio in this case suggests that massive hemolysis could account for all of the transaminase abnormalities.

The predictive value of a positive DAT for an immune etiology in a patient with hemolytic anemia is 83% \[[@B9]\]. DAT reactivity in our patient was 4+ to polyspecific, 4+ to IgG and negative to C3. The patient\'s serum reacted with all reagent RBCs tested by the indirect antiglobulin test. Adsorption of aliquots of serum with ZZAP-treated autologous RBCs failed to remove all reactivity (ZZAP is a papain and dithiothreitol reagent used to clear autoantibody from the patient\'s serum). Adsorption of aliquots of the patient\'s serum with R1R1, R2R2, and RBC samples revealed the presence of an autoantibody with \'e-like\' specificity in the adsorbed serum. Serum antibody reactivity was consistent with a warm autoantibody (panagglutinin) and an antibody with \'e-like\' specificity at anti-human globulin. These results could be consistent with either a warm autoimmune hemolytic anemia (WAIHA) or a drug-induced immune hemolytic anemia (DIIHA) with autoantibody formation (alpha-methyldopa type), which could explain the persistence of hemolysis in this case despite the discontinuation of metformin. Unlike DIIHAs involving neoantigen (immune complex) formation or drug adsorption onto the RBCs, hemolysis owing to drug-induced autoantibodies can persist for several days to months after the drug is stopped. The presence of an autoantibody directed to the Rh system (\'e-like\' specificity) can occur with WAIHA but is more commonly seen with DIIHA \[[@B10]\]. The strength of the DAT reactivity does not necessarily argue for a warm autoantibody; Joshua et al. have shown that the DAT is strongly positive (at least 2+) in 75% of patients with drug-associated hemolysis \[[@B11]\].

The possible mechanism of metformin-induced hemolytic anemia discussed here is different from that proposed by Kashyap and Kashyap in their report \[[@B2]\]. Their patient\'s DAT was positive for anti-C3 and negative for anti-IgG, which suggests the formation of an antibody against the erythrocyte-drug complex. In contrast, our patient\'s DAT was consistent with autoantibody formation. This is not necessarily a contradiction, since it has been shown that the same drug can cause many if not all of the mechanisms of DIIHA. In fact, one mechanism may simply be more pronounced and identifiable in a particular patient. Observations of DIIHA caused by third-generation cephalosporins support the notion of multiple mechanisms for the same drug \[[@B12]\].

Unfortunately, stored samples of this patient\'s blood are not available to test for drug-dependent antibodies. Ultimately, we cannot be certain whether this patient had WAIHA or drug-induced hemolysis caused by an autoantibody. If he did have WAIHA, we are unable to find any clear precipitating cause for his catastrophic hemolysis other than the initiation of metformin.

Conclusion
==========

This patient developed fulminant and fatal Coombs-positive hemolytic anemia that was temporally related to the initiation of metformin treatment, in the absence of any other likely cause. The Naranjo probability score is 3 (\'possible\') for a metformin drug reaction, but in view of the fatal outcome we think it is important to make clinicians aware of the possibility of rare but severe hemolysis with metformin treatment.
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